These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 37417197)

  • 1. Pharmacokinetics and pharmacodynamics of an oral formulation of decitabine and tetrahydrouridine.
    Lau H; Woost PG; Friedrich U; Clausen WHO; Jacobberger JW; Saunthararajah Y
    Eur J Haematol; 2023 Sep; 111(3):345-355. PubMed ID: 37417197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral tetrahydrouridine and decitabine for non-cytotoxic epigenetic gene regulation in sickle cell disease: A randomized phase 1 study.
    Molokie R; Lavelle D; Gowhari M; Pacini M; Krauz L; Hassan J; Ibanez V; Ruiz MA; Ng KP; Woost P; Radivoyevitch T; Pacelli D; Fada S; Rump M; Hsieh M; Tisdale JF; Jacobberger J; Phelps M; Engel JD; Saraf S; Hsu LL; Gordeuk V; DeSimone J; Saunthararajah Y
    PLoS Med; 2017 Sep; 14(9):e1002382. PubMed ID: 28880867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of tetrahydrouridine on pharmacokinetics and pharmacodynamics of oral decitabine.
    Lavelle D; Vaitkus K; Ling Y; Ruiz MA; Mahfouz R; Ng KP; Negrotto S; Smith N; Terse P; Engelke KJ; Covey J; Chan KK; Desimone J; Saunthararajah Y
    Blood; 2012 Feb; 119(5):1240-7. PubMed ID: 22160381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subchronic oral toxicity study of decitabine in combination with tetrahydrouridine in CD-1 mice.
    Terse P; Engelke K; Chan K; Ling Y; Sharpnack D; Saunthararajah Y; Covey JM
    Int J Toxicol; 2014; 33(2):75-85. PubMed ID: 24639139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma pharmacokinetics and oral bioavailability of 3,4,5,6-tetrahydrouridine, a cytidine deaminase inhibitor, in mice.
    Beumer JH; Eiseman JL; Parise RA; Florian JA; Joseph E; D'Argenio DZ; Parker RS; Kay B; Covey JM; Egorin MJ
    Cancer Chemother Pharmacol; 2008 Aug; 62(3):457-64. PubMed ID: 18008070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of gemcitabine (2',2'-difluoro-2'-deoxycytidine) pharmacokinetics, metabolism, and bioavailability in mice by 3,4,5,6-tetrahydrouridine.
    Beumer JH; Eiseman JL; Parise RA; Joseph E; Covey JM; Egorin MJ
    Clin Cancer Res; 2008 Jun; 14(11):3529-35. PubMed ID: 18519786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma pharmacokinetics and oral bioavailability of the 3,4,5,6-tetrahydrouridine (THU) prodrug, triacetyl-THU (taTHU), in mice.
    Beumer JH; Eiseman JL; Gilbert JA; Holleran JL; Yellow-Duke AE; Clausen DM; D'Argenio DZ; Ames MM; Hershberger PA; Parise RA; Bai L; Covey JM; Egorin MJ
    Cancer Chemother Pharmacol; 2011 Feb; 67(2):421-30. PubMed ID: 20443002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined inhibition of histone deacetylase and cytidine deaminase improves epigenetic potency of decitabine in colorectal adenocarcinomas.
    Tang Z; Liu L; Borlak J
    Clin Epigenetics; 2023 May; 15(1):89. PubMed ID: 37208732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A pilot clinical trial of the cytidine deaminase inhibitor tetrahydrouridine combined with decitabine to target DNMT1 in advanced, chemorefractory pancreatic cancer.
    Sohal D; Krishnamurthi S; Tohme R; Gu X; Lindner D; Landowski TH; Pink J; Radivoyevitch T; Fada S; Lee Z; Shepard D; Khorana A; Saunthararajah Y
    Am J Cancer Res; 2020; 10(9):3047-3060. PubMed ID: 33042633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral and intravenous pharmacokinetics of 5-fluoro-2'-deoxycytidine and THU in cynomolgus monkeys and humans.
    Holleran JL; Beumer JH; McCormick DL; Johnson WD; Newman EM; Doroshow JH; Kummar S; Covey JM; Davis M; Eiseman JL
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):803-11. PubMed ID: 26321472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pilot clinical trial of oral tetrahydrouridine/decitabine for noncytotoxic epigenetic therapy of chemoresistant lymphoid malignancies.
    Hill B; Jagadeesh D; Pohlman B; Dean R; Parameswaran N; Chen J; Radivoyevitch T; Morrison A; Fada S; Dever M; Robinson S; Lindner D; Smith M; Saunthararajah Y
    Semin Hematol; 2021 Jan; 58(1):35-44. PubMed ID: 33509441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis, and pharmacological evaluation of fluorinated tetrahydrouridine derivatives as inhibitors of cytidine deaminase.
    Ferraris D; Duvall B; Delahanty G; Mistry B; Alt J; Rojas C; Rowbottom C; Sanders K; Schuck E; Huang KC; Redkar S; Slusher BB; Tsukamoto T
    J Med Chem; 2014 Mar; 57(6):2582-8. PubMed ID: 24520856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tetrahydrouridine inhibits cell proliferation through cell cycle regulation regardless of cytidine deaminase expression levels.
    Funamizu N; Lacy CR; Fujita K; Furukawa K; Misawa T; Yanaga K; Manome Y
    PLoS One; 2012; 7(5):e37424. PubMed ID: 22616006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epimer interconversion, isomerization, and hydrolysis of tetrahydrouridine: implications for cytidine deaminase inhibition.
    Xiang TX; Niemi R; Bummer P; Anderson BD
    J Pharm Sci; 2003 Oct; 92(10):2027-39. PubMed ID: 14502542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased CDA expression/activity in males contributes to decreased cytidine analog half-life and likely contributes to worse outcomes with 5-azacytidine or decitabine therapy.
    Mahfouz RZ; Jankowska A; Ebrahem Q; Gu X; Visconte V; Tabarroki A; Terse P; Covey J; Chan K; Ling Y; Engelke KJ; Sekeres MA; Tiu R; Maciejewski J; Radivoyevitch T; Saunthararajah Y
    Clin Cancer Res; 2013 Feb; 19(4):938-48. PubMed ID: 23287564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High cytidine deaminase expression in the liver provides sanctuary for cancer cells from decitabine treatment effects.
    Ebrahem Q; Mahfouz RZ; Ng KP; Saunthararajah Y
    Oncotarget; 2012 Oct; 3(10):1137-45. PubMed ID: 23087155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics, metabolism, and oral bioavailability of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine in mice.
    Beumer JH; Eiseman JL; Parise RA; Joseph E; Holleran JL; Covey JM; Egorin MJ
    Clin Cancer Res; 2006 Dec; 12(24):7483-91. PubMed ID: 17138702
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Säll C; Fogt Hjorth C
    Xenobiotica; 2022 Jan; 52(1):1-15. PubMed ID: 34913834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tetrahydrouridine, cytidine analogues, and hemoglobin F.
    DeSimone J; Heller P; Molokie RE; Hall L; Zwiers D
    Am J Hematol; 1985 Mar; 18(3):283-8. PubMed ID: 2579548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study.
    Savona MR; Odenike O; Amrein PC; Steensma DP; DeZern AE; Michaelis LC; Faderl S; Harb W; Kantarjian H; Lowder J; Oganesian A; Azab M; Garcia-Manero G
    Lancet Haematol; 2019 Apr; 6(4):e194-e203. PubMed ID: 30926081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.